Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Coherus Biosciences ( (CHRS) ) is now available.
On February 4, 2026, Coherus Oncology, Inc. announced a clinical supply agreement with Janssen Research & Development, LLC to evaluate tagmokitug (CHS-114), its investigational anti-CCR8 cytolytic monoclonal antibody, in combination with Janssen’s T-cell engaging bispecific antibody pasritamig in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer. Under the agreement, Janssen will supply pasritamig while Coherus will sponsor the trial, and both companies will retain full commercial rights to their respective compounds, underscoring a collaborative but non-exclusive approach that could broaden future combination therapy options if the study proves successful.
The most recent analyst rating on (CHRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.
Spark’s Take on CHRS Stock
According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.
The score is held back primarily by weak financial performance (sharp revenue decline, negative operating profitability, and consistently negative operating/free cash flow). Technicals show strong recent momentum but with clear overbought signals, adding near-term risk. The latest earnings call was a positive offset due to LOQTORZI growth, cost discipline, and liquidity improvements, but execution challenges remain.
To see Spark’s full report on CHRS stock, click here.
More about Coherus Biosciences
Coherus Oncology, Inc. is a biopharmaceutical company focused on developing oncology therapeutics, including investigational monoclonal antibodies and other immune-targeting agents, for the treatment of advanced cancers such as metastatic castration-resistant prostate cancer.
Average Trading Volume: 1,894,770
Technical Sentiment Signal: Buy
Current Market Cap: $262.3M
See more insights into CHRS stock on TipRanks’ Stock Analysis page.